EUCTR2011-002731-26-ITActive, not recruitingNot Applicable
An open-label, multi-center, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- OVARTIS FARMA
- Enrollment
- 700
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Male or female patients >18 years of age who have signed an informed consent. 2. Patients with Type 1 or Type 2 DM (according to ADA or WHO guidelines). 3. Patients diagnosed with visual impairment due to focal or diffuse DME in at least one eye for whom no suitable therapeutic alternatives exist (i.e. existing therapies, e.g. laser photocoagulation, have failed or are not indicated). 4. If both eyes are eligible, the one with the worst visual acuity, as assessed at Visit 1, will be selected for treatment unless, based on medical reasons, the investigator deems the other eye the more appropriate candidate for treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 630
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
Exclusion Criteria
- •Ocular concomitant conditions/ diseases:1.Concomitant conditions in the study eye which could, in the opinion of the investigator, prevent the improvement of visual acuity while on treatment;2.Active intraocular inflammation in either eye;3.Any active infection in either eye;4.History of uveitis in either eye;5.Structural damage within 0.5 disc diameter of the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), epiretinal membrane involving fovea or organized hard exudate plaques;6.Ocular disorders in the study eye that may confound interpretation of results, compromise visual acuity or require medical or surgical intervention during the program period, including cataract, retinal vascular occlusion, retinal detachment, macular hole or choroidal neovascularization of any cause;7.Uncontrolled glaucoma in either eye;8.Neovascularization of the iris in either eye;9.Evidence of vitreomacular traction in either eye;10.Active proliferative diabetic retinopathy in the study eye;11.Patients who are monocular or have a BCVA score in the non-study eye = 24 letters at Visit 1. Ocular treatments:12.Panretinal laser photocoagulation in the study eye within 6 months prior to program entry;13.Focal/grid laser photocoagulation in the study eye within 3 months prior to program entry;14.Treatment with anti-angiogenic drugs within 1 month prior to enrollment;15. Any intraocular surgery in the study eye within 3 months prior to enrollment;16.History of vitrectomy in study eye. Systemic conditions or treatments:17.Renal failure requiring dialysis or renal transplant OR renal insufficiency with creatinine levels > 2.0 mg/dl;18.Patient with HbA1c = 12%;19.Hypertension uncontrolled by medication;20.Untreated hypertension or change in antihypertensive treatment within 3 months preceding screening;21.Known hypersensitivity to ranibizumab or any component of the ranibizumab formulation. Compliance/ Administrative:22.Pregnant or nursing (lactating) women;23.Women of childbearing potential UNLESS using effective contraception during treatment;24.Inability to comply with program procedures.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Access Program for Asfotase AlfaHypophosphatasiaEUCTR2015-000809-39-FRAlexion Pharma International Sàrl100
Active, not recruiting
Not Applicable
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available TherapiesEUCTR2009-017671-22-BEEisai Limited500
Completed
Unknown
Trastuzumab deruxtecan for subjects with HER2 mutated metastatic NSCLCJPRN-jRCT2071220096eno Shizuko30
Approved For Marketing
Not Applicable
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.
Active, not recruiting
Phase 1
An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trialsSolid tumorsMedDRA version: 12.1Level: LLTClassification code 10065147Term: Malignant solid tumorEUCTR2009-016834-28-BEovartis Pharma Services AG